Inhibition of ErbB1 and ErbB2 by lapatinib ditosylate, a dual kinase inhibitor: Promising activity in pretreated advanced breast cancer

Clinical Breast Cancer

Volumn 4, Issue 6, 2004, Pages 398-400

  Maung, Kavita ^a   O'Shaughnessy, Joyce A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TOXICITY; MULTICENTER STUDY;

EID: 1842530209     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-8209(11)70826-6     Document Type: Article

References (18)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
2. Arteaga C. Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist 2002; 7(suppl 4): 31-39.
3. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auziliary subunit of NDF and EGF receptors: Implications for breast cancer. EMBO J 1996; 15:254-264.
4. Kurebayashi J. Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer 2001; 8:45-51.
5. Newby J, Johnston S, Smith I, et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997; 3:1643-1651.
6. Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D, Brankovic-Magic M, et al. Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease. J Exp Clin Cancer Res 1999; 18:347-355.
7. Sridhar S, Seymour L, Shepherd F. Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003; 4:397-406.
8. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 2000; 1:12-21.
9. Kris M, Natale R, Herbst R, et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21: 292a (Abtract #1166).
10. Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (NSCLC) (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21:298a (Abtract #1188).
11. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774 following platinum based chemotherapy in patients with advanced EGFR expressing non-small cell lung cancer Proc Am Soc Clin Oncol 2001; 20: 310a (Abtract #1235).
12. Johnson D, Herbst R, Giaccone G, et al. ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients wirh advanced non-small cell lung cancer (NSCLC): Results from a phase III clinical trial (INTACT 2). Ann Oncol 2002; 13:127 (Abstract #468O).
13. Robertson JFR, Guttridge E, Cheung KL, et al. Gefitnib (ZD1839) is active in acquired tamixifen (TAM)-resitant oestrogen receptor (ER)-positive and ER-negative breast cancer: Results from a phase II study. Proc Am Soc Clin Oncol 2003; 22: 7 (Abtract #23).
14. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2003; 22: 7 (Abtract #24).
15. Anderson N, Ahmad T, Chan K, et al. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001; 94:774-782.
16. Moulder S, Yakes E, Muthuswamy S, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61:8887-8895.
17. Xia W, Mullin R, Keith B, et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk/2 and AKT pathways. Oncogene 2002; 21:6255-6263.
18. Burris H, Hurwitz H, Dees C, et al. EGF10004: A randomized, multicenter, phase Ib study of the safety, biologic activity and clinical efficacy of the dual kinase inhibitor GW572016. Breast Cancer Res Treat 2003; 77. Abstract #39 (Late-breaking abstract). Available online through www.sabcs.org.